Delivery Order SPE2DB22D2206-SPE2DB24FKB55

Award Date 8/29/24
Potential Completion Date 8/30/24
Potential Value $6.1K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award is for the pharmaceutical product Dupixent 300 mg/2 ml pen, 2 ml, awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The $18,856.42 firm fixed-price delivery order contract has a completion date of March 6, 2025. This award is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. The IDC...
This federal contract award is for the pharmaceutical product Dupixent 300 mg/2 ml pen 2 ml, awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation. The single-award, indefinite delivery contract (IDC) has a potential value of $999,999,999.00 and a performance period through December 31, 2025. This IDC serves as the primary contract vehicle for AmerisourceBergen Drug Corp to deliver pharmaceutical products...
This federal contract award is for the pharmaceutical product Dupixent 300 mg/2 ml pen in a 2 ml size. The contract, awarded by the Defense Logistics Agency (DLA), was granted to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, on January 28, 2025. The award has a ceiling value of $17,149.48 and is a firm fixed-price delivery order contract with a completion date of January 29, 2025. The contract does not have a set-aside designation. AmerisourceBergen holds a significant...
This federal contract award is for the pharmaceutical product Dupixent 300 mg/2 ml pen with a ceiling value of $35,108.30. The contract was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA). The contract is a delivery order under an Indefinite Delivery Contract (IDC) valued at $999,999,999 that Amerisourcebergen holds with the DLA Troop Support Medical, which serves as a primary vehicle for...
This federal contract award is for the delivery of the pharmaceutical product Dupixent (300 mg/2 ml pen, 2 ml) to the Defense Logistics Agency (DLA). The fixed-price delivery order contract is valued at $11,130.10 and has an ultimate completion date of January 2, 2025. The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. This contract is associated with a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen holds...
This federal contract award is for the pharmaceutical product Dupixent 300 mg/2 ml pen. The award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order with a firm fixed price of $3,441.69 and a completion date of December 19, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and...
This federal contract award is for the pharmaceutical product Dupixent 300 mg/2 ml pen, awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $10,805.87 firm fixed price delivery order contract has a completion date of May 2, 2024 and was awarded by the Defense Logistics Agency (DLA), a defense agency. The contract is not designated with a set-aside requirement, indicating open competition. Amerisourcebergen holds a $999,999,999...
This federal contract award, valued at $17,738.47, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is for the delivery of Dupixent 300 mg/2 ml pens, with an ultimate completion date of April 23, 2025. The contract is a Firm Fixed Price Delivery Order, without any set-aside designation, indicating open competition. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery...
This federal contract award is for the pharmaceutical product Dupixent 300 mg/2 ml pen, 2 ml, with a ceiling value of $15,415.79. The contract was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency, a defense agency. This is a delivery order contract with a firm fixed price pricing type. The contract has an ultimate completion date of May 28, 2025 and was awarded on May 27, 2025. The award is not a...
This federal contract award is for the pharmaceutical product Dupixent 300 mg/2 ml pen, 2 ml, with a ceiling value of $9,195.61. The contract was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA), a defense agency. The award is a delivery order under an Indefinite Delivery Contract (IDC) valued at $999,999,999 held by AmerisourceBergen with the DLA Troop Support Medical, which provides a comprehensive range of pharmaceutical...
  • SPE2DB22D2206
    Indefinite Delivery Contract
  • SPE2DB22D2206-SPE2DB24FKB55
    Delivery Order

This federal contract award is for the pharmaceutical product Dupixent 300 mg/2 ml pen, 2 ml, awarded to Amerisourcebergen Drug Corp by the Defense Logistics Agency (DLA). The award is a delivery order under a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999 through December 2025, which provides a range of medical commodities to military treatment programs and facilities worldwide. The contract has a ceiling value of $6,130.34 and a completion date of August 30, 2024. This award does not have a set-aside designation. Amerisourcebergen, a major pharmaceutical distributor, is the prime contractor for this delivery order, which involves the supply of this critical care medication to the DLA to support the healthcare needs of military personnel, veterans, and other federal beneficiaries.

Generated 11/28/24, 9:14 AM